Publications by authors named "Fredrik Lund"

Background: Polyautoimmunity is defined as having 2 or more autoimmune diseases. Little is known about polyautoimmunity in patients with cutaneous lupus erythematosus (CLE).

Objectives: To estimate prevalence and 5-year incidence of non-lupus erythematosus (LE) autoimmune diseases in patients with CLE.

View Article and Find Full Text PDF

Objectives: Anodal transcranial direct current stimulation (tDCS) of primary motor cortex (M1) and cathodal of the primary sensory cortex (S1) have previously shown to modulate the sensory thresholds when administered with the reference electrode located over the contralateral supraorbital area (SO). Combining the two stimulation paradigms into one with simultaneous stimulation of the two brain areas (M1 + S1 - tDCS) may result in a synergistic effect inducing a prominent neuromodulation, noticeable in the pain thresholds. The aim of this study is to assess the efficacy of the novel M1 + S1 - tDCS montage compared to sham-stimulation in modulating the pain thresholds in healthy adults.

View Article and Find Full Text PDF

Whole-cell bioconversion of technical lignins using Pseudomonas putida strains overexpressing amine transaminases (ATAs) has the potential to become an eco-efficient route to produce phenolic amines. Here, a novel cell growth-based screening method to evaluate the in vivo activity of recombinant ATAs towards vanillylamine in P. putida KT2440 was developed.

View Article and Find Full Text PDF

Introduction: Victims of severe hypothermia and cardiac arrest may appear dead. They are often unresponsive to on-scene resuscitation including defibrillation while profoundly hypothermic. Several cases of extreme hypothermia and prolonged cardiac arrest with good outcome have been published.

View Article and Find Full Text PDF

The authors report on limb salvage in 10 cases of "end-point ischemia," already scheduled for urgent amputation, selected from a group of 42 atherosclerotic cases with critical limb ischemia according to the definition of the Second European Consensus Document on Critical Limb Ischemia. Patients were treated for 3 to 4 weeks with intravenous infusions of the rheologic, antioxidant and endotheliumprotective flavonoid mixture 0-(beta-hydroxyethyl)-rutosides (HR) (Venoruton; Zyma, now Novartis) which improves microvascular blood perfusion and possesses antiedematous effects. The infusions were combined with oral anticoagulation (Waran) which was continued afterwards as long-term treatment for at least 2 years.

View Article and Find Full Text PDF